Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice

Critical Care

Volumn 15, Issue 3, 2011, Pages

  Gu, Jianteng ^a,b   Sun, Pamela ^a   Zhao, Hailin ^a   Watts, Helena R ^a   Sanders, Robert D ^a   Terrando, Niccolo ^c   Xia, Peiyuan ^b   Maze, Mervyn ^c   Ma, Daqing ^a,d  

^a Faculty of Medicine Imperial College London Chelsea and Westminster Campus ^*  (United Kingdom)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPAMEZOLE; DEXMEDETOMIDINE; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 4; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA REPERFUSION INJURY; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ACUTE KIDNEY FAILURE; ANIMAL; C57BL MOUSE; CELL LINE; METABOLISM; PATHOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; CELL LINE; DEXMEDETOMIDINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; PROTECTIVE AGENTS; REPERFUSION INJURY;

EID: 79959410406     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10283     Document Type: Article

References (45)

1. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004, 364:1814-1827. 10.1016/S0140-6736(04)17406-0, 15541456.
2. Stafford-Smith M, Shaw A, Swaminathan M. Cardiac surgery and acute kidney injury: emerging concepts. Curr Opin Crit Care 2009, 15:498-502. 10.1097/MCC.0b013e328332f753, 19812485.
3. Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998, 153:557-566. 10.1016/S0002-9440(10)65598-8, 1852972, 9708815.
4. Kashyap VS, Cambria RP, Davison JK, L'Italien GJ. Renal failure after thoracoabdominal aortic surgery. J Vasc Surg 1997, 26:949-955. 10.1016/S0741-5214(97)70006-5, 9423709.
5. Kupiec-Weglinski JW, Busuttil RW. Ischemia and reperfusion injury in liver transplantation. Transplant Proc 2005, 37:1653-1656. 10.1016/j.transproceed.2005.03.134, 15919422.
6. Sear JW. Kidney dysfunction in the postoperative period. Br J Anaesth 2005, 95:20-32. 10.1093/bja/aei018, 15531622.
7. Borthwick E, Ferguson A. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ 2010, 341:c3365. 10.1136/bmj.c3365, 20603317.
8. Englberger L, Suri RM, Greason KL, Burkhart HM, Sundt TM, Daly RC, Schaff HV. Deep hypothermic circulatory arrest is not a risk factor for acute kidney injury in thoracic aortic surgery. J Thorac Cardiovasc Surg 2011, 141:552-558. 10.1016/j.jtcvs.2010.02.045, 20392457.
9. Cerda J, Lameire N, Eggers P, Pannu N, Uchino S, Wang H, Bagga A, Levin A. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 2008, 3:881-886. 10.2215/CJN.04961107, 18216347.
10. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004, 114:5-14. 437979, 15232604.
11. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000, 190:255-266. 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6, 10685060.
12. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010, 6:224-235. 10.1038/nrneph.2010.16, 20177402.
13. Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm 2010, 2010:704202. 2902053, 20628516.
14. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342. 10.1038/nri1594, 15803152.
15. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179. 10.1097/01.shk.0000225404.51320.82, 16878026.
16. Hoste EA, Kellum JA. Incidence, classification, and outcomes of acute kidney injury. Contrib Nephrol 2007, 156:32-38.
17. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000, 90:699-705. 10.1097/00000539-200003000-00035, 10702460.
18. Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs 2007, 8:25-33.
19. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502:87-97. 10.1016/j.ejphar.2004.08.044, 15464093.
20. Kuhmonen J, Pokorny J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen P, Sivenius J. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 1997, 87:371-377. 10.1097/00000542-199708000-00025, 9286902.
21. Billings F, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT. alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 2008, 295:F741-748. 10.1152/ajprenal.90244.2008, 18579700.
22. Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR, Sladen RN. Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth 2006, 18:422-426. 10.1016/j.jclinane.2006.02.005, 16980158.
23. Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996, 24:947-952. 10.1097/00003246-199606000-00012, 8681596.
24. Solez K, Ideura T, Silvia CB, Hamilton B, Saito H. Clonidine after renal ischemia to lessen acute renal failure and microvascular damage. Kidney Int 1980, 18:309-322. 10.1038/ki.1980.141, 7463946.
25. Tsutsui H, Sugiura T, Hayashi K, Ohkita M, Takaoka M, Yukimura T, Matsumura Y. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol 2009, 603:73-78. 10.1016/j.ejphar.2008.12.012, 19101535.
26. Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D. Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood) 235:886-891.
27. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009, 110:1077-1085. 10.1097/ALN.0b013e31819daedd, 19352168.
28. Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009, 20:713-720. 10.1681/ASN.2008070712, 2663824, 19144758.
29. Satake A, Takaoka M, Nishikawa M, Yuba M, Shibata Y, Okumura K, Kitano K, Tsutsui H, Fujii K, Kobuchi S, Ohkita M, Matsumura Y. Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney Int 2008, 73:308-317. 10.1038/sj.ki.5002690, 18004295.
30. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484. 2323334, 18431461.
31. Franks NP, Lieb WR. Volatile general anaesthetics activate a novel neuronal K+ current. Nature 1988, 333:662-664. 10.1038/333662a0, 2453807.
32. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
33. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004. 10.1038/nrd1902, 16341064.
34. Dahmani S, Rouelle D, Gressens P, Mantz J. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 2005, 103:969-977. 10.1097/00000542-200511000-00011, 16249671.
35. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003, 96:524-531.
36. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364. 10.1038/nri2079, 17457343.
37. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680. 10.1038/90609, 11477402.
38. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007, 117:2847-2859. 10.1172/JCI31008, 1974864, 17853945.
39. Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004, 32:1322-1326. 10.1097/01.CCM.0000128579.84228.2A, 15187514.
40. Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 2001, 86:650-656. 10.1093/bja/86.5.650, 11575340.
41. Sanders RD, Hussell T, Maze M. Sedation & immunomodulation. Crit Care Clin 2009, 25:551-570. 10.1016/j.ccc.2009.05.001, 19576530.
42. Memis D, Hekimoglu S, Vatan I, Yandim T, Yuksel M, Sut N. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth 2007, 98:550-552. 10.1093/bja/aem017, 17363413.
43. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent) 2001, 14:13-21.
44. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002, 283:R287-295.
45. Junaid A, Cui L, Penner SB, Smyth DD. Regulation of aquaporin-2 expression by the alpha(2)-adrenoceptor agonist clonidine in the rat. J Pharmacol Exp Ther 1999, 291:920-923.